The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
A multicentre, open‐label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors
Open accessAbstract
Introduction: Emicizumab is a recombinant humanized bispecific monoclonal antibody mimicking the cofactor function of activated factor VIII. Aim: In this multicentre, open‐label study (HOHOEMI), we evaluated the efficacy, safety and pharmacokinetics of emicizumab in Japanese paediatric patients aged <12 years with severe haemophilia A without factor VIII (FVIII) inhibitors. Methods: Emicizumab was administered subcutaneously, with four loading doses of 3 mg/kg every week followed by maintenance doses of 3 mg/kg every 2 weeks (Q2W) or 6 mg/kg every 4 weeks (Q4W) in 6 and 7 patients, respectively. Results: All patients completed at least 24 weeks of treatment. Baseline ages ranged from 4 months to 10 years, and all patients had been treated with FVIII prophylaxis prior to enrolment except a 4‐month‐old patient untreated with FVIII previously. In the respective Q2W and Q4W cohorts, 2/6 and 5/7 patients experienced no treated bleeding events, and annualized bleeding rates for treated bleeding events were 1.3 (95% confidence interval [CI], 0.6‐2.9) and 0.7 (95% CI, 0.2‐2.6). All caregivers preferred emicizumab to the patient's previous treatment. Only one related adverse event (injection site reaction) was observed. There were no thromboembolic events or thrombotic microangiopathy. Individual trough plasma concentrations of emicizumab were within the variability observed in preceding adult/adolescent studies. All patients tested negative for anti‐emicizumab antibodies. Conclusions: Emicizumab administered Q2W or Q4W was efficacious and safe in paediatric patients with severe haemophilia A without inhibitors. This study was registered at http://www.clinicaltrials.jp (JapicCTI‐173710).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DEN UIJL, I. E. M., FISCHER, K., VAN DER BOM, J. G., GROBBEE, D. E., ROSENDAAL, F. R., & PLUG, I. (2011) · Haemophilia · doi:10.1111/j.1365-2516.2010.02383.x · Cited by 214
Cited by
Callaghan, M. U., Negrier, C., Paz-Priel, I., Chang, T., Chebon, S., Lehle, M., Mahlangu, J., Young, G., Kruse-Jarres, R., Mancuso, M. E., et al. (2021) · Blood · doi:10.1182/blood.2020009217 · Cited by 307
Self-citationPharmacokinetics and Associated Efficacy of Emicizumab in Humans: A Systematic Review
Donners, A. A. M. T., Rademaker, C. M. A., Bevers, L. A. H., Huitema, A. D. R., Schutgens, R. E. G., Egberts, T. C. G., & Fischer, K. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01042-w · Cited by 40
Metadata
- Authors
- Shima, M., Nogami, K., Nagami, S., Yoshida, S., Yoneyama, K., Ishiguro, A., Suzuki, T., & Taki, M.
- Venue
- Haemophilia
- Publisher
- Wiley
- Published
- 2019-09-12
- Volume
- 25
- Issue
- 6
- Pages
- 979-987
- ISSN
- 1351-8216 (ISSN-L)
- 1365-2516
- OpenAlex
- W2972682000
- Cited by
- 161
- References
- 1
- FWCI
- 11.94
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A multicentre, open‐label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors. https://app.cochat.ai/papers/10.1111/hae.13848
- The paper
- Shima, M., Nogami, K., Nagami, S., Yoshida, S., Yoneyama, K., Ishiguro, A., Suzuki, T., & Taki, M. (2019). A multicentre, open‐label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors. Haemophilia. https://doi.org/10.1111/hae.13848
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.